Covid-19 during the third wave in Mexico: symptoms and vaccination as protective factor in Durango

Edgar Olivas-Calderón, Francisco Javier García-Alvarado, Hector Alberto Delgado-Aguirre, Rolando Adair Facio-Campos



Introduction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was responsible for the pandemic declared in January 2020, the impact of this virus is its high transmission rate where symptoms appear 2 to 14 days after exposure in Mexico the vaccination against SARS-CoV-2 has been very important. Objective. To evaluate the frequency of SARS-CoV-2, symptoms, and the impact of vaccination in the north of Durango State during the third wave in Mexico. Material and methods. We recruited 917 subjects from Sanitary Jurisdiction #2 (dependent on the Ministry of Health of Durango state) from October 2021 to January 2022. SARS-CoV-2 was diagnosed by RT-PCR in nasopharyngeal swabs. Symptoms and vaccination were evaluated. Results. The total incidence of positive cases was 41.66% (n=382). The presence of fever, cough, anosmia and dysgeusia is positively associated with infection (p<0.05). On the other hand, previous application of the vaccine and having contact with positive subjects 14 days prior to diagnosis yielded a protective OR with respect to the disease (OR = 0.60 and 0.50, respectively) (p<0.05). Conclusions. We observed a relationship between fever, cough, anosmia and dysgeusia with the disease. On the other hand, we observed a protective factor due to vaccination.


Keywords: SARS-CoV-2; Covid-19; symptoms; vaccination; Mexico.


Short title: SARS-CoV-2 symptoms and vaccination in Durango.



Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England journal of medicine. 2020;382(8):727-33. Epub 2020/01/25. doi: 10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID: PMCPMC7092803.

Dirección General de Información en Salud. Covid-19, México: Datos epidemiológicos: México: SINAVE 2020; 2022. Available from:

Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 2019;17(3):181-92. doi: 10.1038/s41579-018-0118-9.

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology. 2020;277(8):2251-61. doi: 10.1007/s00405-020-05965-1.

Saniasiaya J, Islam MA, Abdullah B. Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients. 2021;131(4):865-78. doi: 10.1002/lary.29286.

Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Network Open. 2021;4(1):e2035057-e. doi: 10.1001/jamanetworkopen.2020.35057.

Fernández-Rojas MA, Luna-Ruiz Esparza MA, Campos-Romero A, Calva-Espinosa DY, Moreno-Camacho JL, Mendlovic F, et al. Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico. Scientific reports. 2022;12(1):5241. Epub 2022/03/30. doi: 10.1038/s41598-022-09395-3. PubMed PMID: 35347208; PubMed Central PMCID: PMCPMC8960100.

Covantes-Rosales CE, Barajas-Carrillo VW, Girón-Pérez DA, Toledo-Ibarra GA, Díaz-Reséndiz KJG, Navidad-Murrieta MS, et al. Comparative Analysis of Age, Sex, and Viral Load in Outpatients during the Four Waves of SARS-CoV-2 in A Mexican Medium-Sized City. International journal of environmental research and public health. 2022;19(9). Epub 2022/05/15. doi: 10.3390/ijerph19095719. PubMed PMID: 35565114; PubMed Central PMCID: PMCPMC9104031.

Núñez I, Caro-Vega Y, Belaunzarán-Zamudio PF. Diagnostic precision of local and World Health Organization definitions of symptomatic COVID-19 cases: an analysis of Mexico's capital. Public health. 2022;205:187-91. Epub 2022/03/21. doi: 10.1016/j.puhe.2022.02.010. PubMed PMID: 35306444; PubMed Central PMCID: PMCPMC8831121.

Anaya-Covarrubias JY, Pizuorno A, Mirazo S, Torres-Flores J, Du Pont G, Lamoyi E, et al. COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection. Current Opinion in Pharmacology. 2022;63:102203. doi: 10.1016/j.coph.2022.102203.

Carnalla M, Basto-Abreu A, Stern D, Bautista-Arredondo S, Shamah-Levy T, Alpuche-Aranda CM, et al. Acceptance, refusal and hesitancy of Covid-19 vaccination in Mexico: Ensanut 2020 Covid-19. Salud publica de Mexico. 2021;63(5):598-606. Epub 2022/02/01. doi: 10.21149/12696. PubMed PMID: 35099875.

Monge S, Rojas-Benedicto A, Olmedo C, Martín-Merino E, Mazagatos C, Limia A, et al. Effectiveness of a second dose of an mRNA vaccine against SARS-CoV-2 Omicron infection in individuals previously infected by other variants. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022. Epub 2022/06/11. doi: 10.1093/cid/ciac429. PubMed PMID: 35687580.

Cueto-Robledo G, Navarro-Vergara D-I, Roldan-Valadez E, Garcia-Cesar M, Graniel-Palafox L-E, Cueto-Romero H-D, et al. Pulmonary embolism (PE) prevalence in Mexican-mestizo patients with severe SARS-COV-2 (COVID-19) pneumonia at a tertiary-level hospital: A review. Current Problems in Cardiology. 2022:101208. doi: 10.1016/j.cpcardiol.2022.101208.

Chu DK, Duda S, Solo K, Yaacoub S, Schunemann H. Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis. J Vasc Surg. 2020;72(4):1500-. Epub 2020/09/21. doi: 10.1016/j.jvs.2020.07.040. PubMed PMID: PMC7503118.

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. Jama. 2020;324(8):782-93. Epub 2020/07/11. doi: 10.1001/jama.2020.12839. PubMed PMID: 32648899.

Enlaces refback

  • No hay ningún enlace refback.